Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of subcutaneous Dynepo in anaemia associated with chronic kidney disease
2007-000054-31Phase 4Completed
- Sponsor
- Shire
- Start
- Mar 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoetin delta in Uraemic Anaemia, sponsored by Shire. Primary endpoint: Treatment-emergent adverse events over 2 years. Started Mar 2007; status: completed.
02
Drugs
epoetin delta
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on 2007-000054-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000054-31.